Merck beats on revenue boosted by Keytruda sales, but posts quarterly loss due to Prometheus dealCNBC • 08/01/23
RXDX Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Prometheus Biosciences, Inc. Is Fair to ShareholdersBusiness Wire • 05/24/23
PROMETHEUS BIOSCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDXBusiness Wire • 05/22/23
Horizon Tumbles — Taking Seagen, Prometheus With It — On Reports FTC Could Block Its Amgen TakeoverInvestors Business Daily • 05/16/23
Prometheus Biosciences, Inc. (RXDX) is a Great Momentum Stock: Should You Buy?Zacks Investment Research • 05/12/23
Prometheus Biosciences, Inc. (RXDX) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research • 05/09/23
Prometheus Biosciences Reports First Quarter 2023 Financial Results and Highlights Recent Corporate ProgressGlobeNewsWire • 05/09/23
PROMETHEUS BIOSCIENCES INVESTOR ALERT By the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Prometheus Biosciences, Inc. - RXDXBusiness Wire • 04/21/23
Prometheus Biosciences, Inc. (RXDX) Stock Jumps 69.7%: Will It Continue to Soar?Zacks Investment Research • 04/18/23
Merck's $10.8 billion takeover of Prometheus is a good strategic move that gives it a foothold in immunologyMarket Watch • 04/17/23
Merck Nabs Prometheus Bio For $10.8 Billion As Keytruda Patent Expirations LoomInvestors Business Daily • 04/17/23
RXDX Stock Alert: The $10.8 Billion Reason Prometheus Biosciences Is Surging TodayInvestorPlace • 04/17/23
XPeng Is Charging Higher, but This Biotech Stock Is Monday's Biggest WinnerThe Motley Fool • 04/17/23
Prometheus Biosciences, XPeng and State Street are among the stocks on the moveMarket Watch • 04/17/23
Shareholder Alert: Ademi LLP investigates whether Prometheus Biosciences, Inc. has obtained a Fair Price in its transaction with MerckPRNewsWire • 04/17/23